STOPTUSSIN

This brand name is authorized in Lithuania

Active ingredients

The drug STOPTUSSIN contains a combination of these active pharmaceutical ingredients (APIs):

1 Butamirate
UNII 67HP51L98R - BUTAMIRATE CITRATE

Butamirate (or brospamin) is a cough suppressant. It binds to the cough center in the medulla oblongata, more specifically the dextromethorphan-binding site in guinea pig brain with high affinity.

Read about Butamirate
2 Guaifenesin
UNII 495W7451VQ - GUAIFENESIN

Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions. Guaifenesin is over-the-counter drug for the treatment of cough and common cold.

Read about Guaifenesin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
R05FB02 Cough suppressants and expectorants R Respiratory system → R05 Cough and cold preparations → R05F Cough suppressants and expectorants, combinations → R05FB Other cough suppressants and expectorants
Discover more medicines within R05FB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: LT Valstybinฤ— vaistลณ kontrolฤ—s tarnyba Identifier(s): 1008987

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.